ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Tafinlar Subgroup Data Shows Median OS of 20 Months

October 31, 2014

ORI Finds St. Mary’s Data Managers Falsified Data In BCPT

September 8, 1995

Proceedings Initiated Against Two Physicians At Dana-Farber

April 7, 1995

AACR Polls Members On Tentative Date for Annual Meeting

April 11, 2003

NCI Backed Studies Indicate Overweight Not Much Of a Cancer Risk Factor

June 19, 1987

In Brief: House Appropriations Committee Gives NCI $725 Million, Smallest Increase Since 1970

June 1, 1975